Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$402.70 USD
+3.35 (0.84%)
Updated Dec 31, 2024 04:00 PM ET
After-Market: $402.66 -0.04 (-0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
VRTX 402.70 +3.35(0.84%)
Will VRTX be a Portfolio Killer in January?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock?
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics
Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
Top Stock Reports for T-Mobile, Toyota Motor & Vertex Pharmaceuticals
Other News for VRTX
Yum, Ralph Lauren upgraded: Wall Street’s top analyst calls
Yum, Ralph Lauren upgraded: Wall Street's top analyst calls
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals Inc (VRTX)'s Winning Formula: Financial Metrics and Competitive Strengths
Crispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025